Researchers at City of Hope found that white button mushroom supplements reduce MDSCs, which weaken the immune system and allow prostate cancer to spread. The study suggests that 'food as medicine' treatments may become evidence-based cancer care.
Researchers at City of Hope have made significant strides in the biology behind our sense of smell, finding new ways to treat esophageal cancer, and improving management of type 2 diabetes. The team's discoveries include a better understanding of odorant receptors and the potential for novel immunotherapies for cancer treatment.
Researchers developed a personalized vaccine to treat rare blood cancer, which nearly doubled disease-free progression time. The vaccine appears safe and effective in activating the immune response against tumor cells.
Researchers at City of Hope and Mount Sinai have demonstrated a combination treatment that increases human insulin-producing beta cells by 700% in mice with type 1 and type 2 diabetes. The study, published in Science Translational Medicine, provides a potential new approach to treating the disease.
Researchers found that a live biotherapeutic product CBM588, when taken orally, can improve health outcomes in people with metastatic kidney cancer. The study, published in Nature Medicine, suggests that the agent may enhance effectiveness of FDA-approved cancer immunotherapies by adjusting the gut microbiome.
A team of researchers from City of Hope has identified novel associations between DNA methylation activity and a subsequent risk of developing kidney failure in type 1 diabetes patients. By analyzing blood samples from over 277 participants, they found stable biomarkers that remained remarkably consistent across years.
Researchers at City of Hope have developed a new approach to target and destroy hard-to-kill leukemia stem cells. The therapy method uses Type II interferon to disrupt the cancer cells' ability to divide, and a T cell engager antibody to create a bridge between the immune system and the leukemia stem cells.
Researchers at City of Hope successfully treated the oldest person to achieve remission for both leukemia and HIV, demonstrating the effectiveness of reduced intensity chemotherapy before a stem cell transplant. The patient, Paul Edmonds, received donor cells resistant to HIV and was cured after nearly three years without antiretrovira...
Scientists at City of Hope discovered a new cellular mechanism that plays a key role in cancer cells' ability to cause disease. The study identified integrin αV and β5 as crucial proteins that partner to spur cancer cell growth, offering a promising target for new therapies.
Researchers at City of Hope and TGen developed a machine-learning tool that can identify half of the cancers in 11 studied types with high accuracy. The innovative 'fragmentomics' approach allows for smaller blood draws, making it more practical for clinical applications.
Researchers at City of Hope have discovered a specific immune cell type that can selectively target and kill cancer cells. The breakthrough could lead to the development of a novel immunotherapy treatment, potentially offering new hope for cancer patients.
A Phase 2B clinical trial, led by City of Hope, found that carvedilol may improve heart health markers and reduce the risk of heart failure in childhood cancer survivors. The study suggests that carvedilol could benefit long-term survivors and those who are highly adherent to the treatment.
A qualitative study by City of Hope highlights the importance of proper patient preparation for unanticipated, inheritable genetic findings prior to tumor sequencing. The research emphasizes the need for scalable educational interventions that facilitate informed consent, such as online tools and applications.
A new therapeutic option has been found for patients with a treatment-resistant tumor mutation called KRAS G12C. The sotorasib and panitumumab combination demonstrated superior progression-free survival rates compared to standard of care.
Researchers aim to validate noninvasive screening test using exosomal microRNAs for early detection of pancreatic ductal adenocarcinoma. The goal is to reduce unnecessary surgeries and improve health equity by including diverse populations in the study.
Researchers at City of Hope have discovered that nongenetic mechanisms play a crucial role in lung cancer patients' development of resistance to the anti-cancer medication sotorasib. The study found that tumor cells can become tolerant to therapeutic treatment without genetic mutations, and that withholding treatment allows them to rev...
The City of Hope will lead the way in integrating complementary therapies into cancer care, supporting holistic treatment for patients. The Cherng Family Center's research and clinical programs aim to advance evidence-based standards for integrative oncology, creating an international destination for its transformational work.
Researchers discovered a potential new target for treating metastatic cancer by blocking the cytosol-to-mitochondria citrate flux process, which induces oxidative stress and cell death. The study's findings provide additional data to support therapy targeting this process for cancer patients with metastasis.
Researchers identified how low TET2 levels fuel rapid growth of acute myeloid leukemia in animal models. The study found that TET2 deficiency sets off biochemical changes enhancing the cancer's ability to spread. This discovery highlights potential therapeutic targets for treating aggressive bone marrow cancer.
Researchers have identified four metabolism-related biomarkers linked to an increased risk of metastatic prostate cancer in Black men. These biomarkers could lead to improved testing and treatments for this high-risk population, who are more than twice as likely to die from the disease.
Researchers at City of Hope have identified new molecular targets on a cell receptor that play a major role in cardiovascular regulation. The findings could lead to improved drugs for heart disease, an unfortunate side effect of some cancer therapies.
City of Hope will conduct Phase 1 clinical trials for novel cell and gene therapy treatments for patients with HIV, acute myeloid leukemia, and severe aplastic anemia. A CAR T therapy for HIV is also being developed to potentially target other diseases.
Researchers developed a targeted chemotherapy that selectively disrupts DNA replication and repair in cancer cells, leaving healthy cells unaffected. The investigational small molecule AOH1996 has been effective in treating various types of solid tumors in preclinical research.
The updated guidelines urge the clinical use of validated geriatric assessments (GA) to guide treatments in patients aged 65 and older. This approach often results in de-escalation or reduction of therapies, reducing side effects and improving quality of life without compromising survival odds.
Researchers at City of Hope have developed a universal donor stem cell therapy that can treat degenerative brain diseases such as Canavan disease and Alzheimer's. The therapy, which uses an 'off-the-shelf' approach, has shown promising results in preclinical studies, reducing toxic accumulation of metabolites and improving motor function.
Researchers at City of Hope identified a previously unknown mechanism by which interleukin-15 (IL-15) interacts with XBP1s to boost natural killer cells' survival and anti-tumor immunity. This finding suggests a promising therapeutic approach for future cancer treatments.
A new study by City of Hope found that neuroendocrine cancer patients value overcoming pain, fatigue, or lack of function over prolonging life. Only half of the time do patients and doctors agree on treatment goals.
Researchers from City of Hope identified how a protein receptor targeted by 33% of all federally approved medications works. This discovery could facilitate pharmaceutical research and lead to the creation of innovative medicines with fewer side effects.
A study found that Medicare Advantage patients are more likely to be treated by less experienced surgeons and have higher mortality rates after complex cancer surgeries. They also experience longer delays in diagnosis and treatment due to prior authorization requirements.
A new combination immunotherapy regimen shows remarkable activity in metastatic colorectal cancer patients without liver metastases, achieving a response rate of 40% and median overall survival exceeding 20 months. The study's findings confirm the importance of the tumor microenvironment in shaping the response to immunotherapy.
The Sheri and Les Biller Family Foundation has donated $10 million to City of Hope to expand its supportive care programs for cancer patients, improving treatment outcomes and quality of life. The partnership aims to establish supportive care as a standard practice in cancer care across the US.
City of Hope researchers present new developments in cell therapy for acute myeloid leukemia and non-small cell lung cancer. A novel smoking cessation program increases patient desire to quit with personalized counseling.
The investigational vaccine targets both the spike and nucleocapsid proteins, producing neutralizing antibodies and inducing T cell responses against SARS-CoV-2. COH04S1 is being studied in Phase 2 trials for immunocompromised patients and as a booster for healthy adult volunteers.
A recent study by City of Hope researchers highlights the limitations of Signatera, a popular liquid biopsy test for detecting colorectal cancer recurrence. The study found that standard-of-care CT scan plus CEA blood draw test was more effective in identifying early disease recurrence.
A Phase 1 clinical trial showed CBM588 significantly improved progression-free survival in patients with metastatic kidney cancer when combined with immunotherapy. The treatment also increased response rates compared to immunotherapy alone, with no significant differences in toxicity.
The five-year grant will be used to mentor junior scientists, leveraging City of Hope's expertise in cancer treatment and patient care. The program will provide students with hands-on experience in cell-based therapies, regulatory approval, and commercialization.
A Phase 2 clinical trial showed sotorasib can shrink tumors and achieve disease control in heavily pretreated patients with advanced colorectal cancer. The study results exceeded the historic benefits linked to approved therapies, offering new hope for a population with limited treatment options.
Researchers identified a mechanism for how genetically defective cells mutate to survive stressful situations, such as drug treatment. Understanding this resistance mechanism could lead to the development of new strategies to delay or prevent cancer drug resistance.
A City of Hope clinical trial showed that patients over 65 experiencing significantly fewer treatment-related side effects when a multidisciplinary team analyzed each case and introduced personalized interventions. The completion of advance directives was also higher in the experimental group.
Scientists at City of Hope and Griffith University developed a novel anti-HIV protein called ZPAMt that can suppress HIV levels in the bone marrow, spleen, and brain of mice. The protein is delivered using exosomes, nanosized parts of cells that can reach difficult-to-access areas of the body.
A Phase 2 trial found that combining cisplatin, gemcitabine, and berzosertib did not prolong progression-free survival in patients with urothelial cancer. The study suggests that berzosertib may have a negative impact on bone marrow, leading to reduced white blood cells and platelets.
Researchers at City of Hope found that advanced colorectal cancer patients with no liver metastases respond to checkpoint inhibitors, achieving a major response in 20% of cases. In contrast, patients with liver metastases showed no positive response to immunotherapy.
Researchers at City of Hope developed a powerful miniature brain platform to study the causes of Alzheimer's disease and test dementia drugs in development. They used human stem cell technology to model sporadic Alzheimer's disease, finding that exposure to serum from blood can induce multiple symptoms.
Yanhong Shi and her team are developing an autologous treatment for Canavan disease using induced pluripotent stem cell (iPSC) technology, which has shown promising results in preclinical studies. The goal is to correct the genetic mutation that causes the disease by introducing a functional ASPA gene into brain cells.
Researchers at City of Hope have identified the genetic changes that occur in breast cancer cells when they become resistant to hormone therapies. These findings suggest that tumor cells can quickly change and rewire signaling pathways to persist despite treatment, providing new opportunities for targeted therapy interventions.
Scientists at City of Hope and Griffith University have developed a novel direct-acting antiviral therapy that targets the genome of SARS-CoV-2, reducing viral load by 99.9%. The treatment uses siRNA technology and lipid nanoparticles to deliver the RNA to lung cells, where it silences viral genes.
A new clinical trial is investigating the effectiveness of white button mushroom tablets in regulating immune systems and reducing prostate-specific antigen (PSA) levels. The study aims to recruit 132 male participants with recurrent prostate cancer, with results indicating potential benefits against prostate cancer.
A novel blood-based test has been developed to identify individuals with lymph node metastasis associated with high-risk T1 colorectal cancer, potentially avoiding unnecessary colon surgery. The test demonstrated high accuracy in detecting lymph node metastasis, exceeding expectations.
City of Hope's Betty Ferrell is honored with the 2021 ONS Lifetime Achievement Award for her decades-long dedication to improving pain management and quality of life for cancer patients. With over $70 million in grant funding, she has trained millions of nurses and clinicians globally on palliative care.
Researchers identified three genetic regions associated with skin pigmentation and severe vitamin D deficiency in African Americans. The study's findings have implications for personalized vitamin D supplementation and potential cancer prevention.